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Psoriasis is a chronic, relapsing and remitting inﬂammatory skin and joint disease that has a prevalence of 2-3% in the world’s
population, whereas of 1–2% in Europe. The traditional concept of psoriasis as the “healthy people’s” disease has been recently
revisedbecauseofever-increasingreportsofassociationswithvariouspathologicalconditions(hypertension,Crohn’sdisease,type
IIdiabetesmellitus,obesity,dyslipidemia,metabolicsyndrome,infectiousconditions).Particularly,advancesinpsoriasistherapies
have introduced biologic agents. All the tumor necrosis factor-alpha inhibitors are associated with an increased risk of developing
active disease in patients with latent tuberculosis infection, because of TNF-α key role against Mycobacterium tuberculosis. For this
reason, exclusion of active tuberculosis and treatment of latent tuberculosis infection are clinical imperatives prior to starting this
therapy. Moreover active surveillance for a history of untreated or partially treated tuberculosis or latent form has already been
shown to be eﬀective in reducing the number of incident tuberculosis cases.
1. Introuction
Psoriasis is a chronic, relapsing and remitting inﬂammatory
skin and joint disease that has a prevalence of 2-3% in
the world’s population [1], whereas of 1-2% in Europe [2].
In Italy, the number of patients aﬀected with psoriasis is
estimated to be greater than 1.7 millions [3]. Men and
women are equally aﬀected and exhibit a bimodal distribu-
tion with a peak between 15 and 30 years of age and another
b e t w e e n5 0a n d6 0y e a r so fa g e[ 1]. Psoriasis results from the
interaction between genetic and environmental factors [4]
and can cause signiﬁcant impairment of physical, emotional,
and psychosocial well-being of patients [5]. The traditional
concept of psoriasis as the “healthy people’s” disease has
been recently revised [5] because of ever-increasing reports
of associations with various pathological conditions, such
as systemic diseases including hypertension, Crohn’s disease,
type II diabetes mellitus, obesity, dyslipidemia, metabolic
syndrome, and infectious conditions [6]. Furthermore, pso-
riasis can also lead to substantial adverse socioeconomic
consequences for patients, since physical disability and
emotionaldistressofpatientscanaﬀecttheirworkfunctions.
For these reasons, psoriasis is associated with lesser work
productivity and a greater number of missed work days
compared to healthy individuals, incurring substantial indi-
rect costs, and adding to the ﬁnancial burden of the disease
together with the incremental economic burden of treating
comorbidities in addition to treating psoriasis compared
to treating psoriasis alone [7, 8]. Up to 30% of 70% of
psoriatic patients require traditional systemic treatments,
such as retinoids, methotrexate, and cyclosporine. Many of
them imply long-term toxicity, treatment resistance, and
potential drug interactions, so only 25% of psoriatic patients
are completely satisﬁed with their treatment [9]. Advances
in psoriasis therapies have introduced biologic agents, whose
immune targeting is successful in treating many immune-
mediated inﬂammatory diseases. All the tumor necrosis
factor-alpha (TNF-α) inhibitors are associated with an
increased risk of developing active disease in patients with
latent tuberculosis infection (LTBI), because TNF-α is a key
cytokine in protective host defense against Mycobacterium
tuberculosis (Mtb) [10, 11]. For this reason, exclusion of
activetuberculosis(TB)andtreatmentofLTBIare,therefore,2 Clinical and Developmental Immunology
clinical imperatives prior to starting anti-TNF-α therapy and
active surveillance for a history of untreated or partially
treated TB or LTBI has already been shown to be eﬀective
in reducing the number of incident TB cases [12–14].
2. PsoriaticDiseasePathogenesis
The pathogenesis of psoriasis includes hyperproliferation
as well as aberrant diﬀerentiation of keratinocytes, dermal
angiogenesis, and inﬂammation. Dermal inﬁltration of
inﬂammatory T cells, dendritic cells (DCs), macrophages,
and neutrophils represents characteristic features of the
disease [2]. Nowadays, the fundamental role played by the
immune system in psoriatic disease pathogenesis is quite
welldeﬁned. T helper (Th)1 and Th17 lymphocytes con-
tribute to the pathogenesis of psoriasis through the release
of inﬂammatory cytokines that promote further recruitment
of immune cells, keratinocyte proliferation, and sustained
inﬂammation [15]. The T lymphocytes involved in lesion
development were initially thought to be Th1 diﬀerentiated,
based on interferon- (IFN-) gamma and interleukin- (IL-)
2 productions. Th17 cells have recently been classiﬁed as
distinct from Th1 and Th2 subsets. They are deﬁned by the
ability to synthesize IL-17 in response to antigen-presenting
cell-derived IL-23 and other diﬀerentiating cytokines. In
addition, Th17 cells have been reported to cosynthesize IL-
17 and IFN-gamma as well as IL-22 [16]. Recently, psoriatic
skin lesions are reported to have increased gene expression
of IL-23, IL-17, and IL-22 [17]. IL-23 is a heterodimeric
cytokine composed of two subunits (p40 subunit, common
with IL-12, and p19 subunit, speciﬁc for IL-23) [18]. IL-
23 is produced by dendritic cells (DCs), macrophages,
and other antigen-presenting cells under the inﬂuence of
s o m eG r a m - p o s i t i v ea sw e l la sG r a m - n e g a t i v eb a c t e r i aa n d
lipopolysaccharides [18]. Several recent studies suggest that
psoriasis is a Th17 cell-mediated disease driven by IL-23
[19].Moreover,TNF-αstimulatesCD11+ inﬂammatoryDCs
to produce IL-23 and IL-20 and appears to be a critical
cytokine for many of the clinical features of psoriasis,
including keratinocyte hyperproliferation, endothelial cell
regulation, and recruitment/eﬀector function of memory T-
cells. All these ﬁndings reinforce that psoriasis pathogenesis
is a complex interaction among genetic, immunological, and
environmental components.
3.ClinicalPhenotype andHistological
PsoriasisFeatures
Clinical diagnosis of psoriasis is relatively easy for a derma-
tologist, especially when the lesions present as erythematous,
sharply demarcated indurated plaques with silvery white
scales. Plaques may have an oval or irregular shape, varying
from one to several centimetres in diameter and are usually
distributed symmetrically on the extensor surfaces of limbs
(mainly elbows and knees), the lower back and the scalp.
Itching is variable, but it is usually absent [20]. These clinical
aspects reﬂect the histopathological ﬁndings observed in
active lesions, characterized by hyperkeratosis, parakeratosis,
diminution, or loss of the granular cell layer, acanthosis of
the epidermal ridges, tortuous and dilated blood vessels,
and perivascular leukocytic inﬁltrate in the dermal papillae
[1]. The clinical and histological features of chronic plaque
psoriasis are generally suﬃcient to make the diagnosis.
Furthermore, psoriasis can present many faces, including
guttata, pustular, and erythrodermic. Guttate psoriasis is
characterized by the acute onset of round, erythematous,
slightly scaling papules over the trunk and extremities. The
face could be involved. The disease is self-limiting; however,
ap r o p o r t i o no fa ﬀected individuals may progress to a
more chronic form of plaque psoriasis. Flares of guttate
lesions may appear during the course of chronic plaque
psoriasis and can follow streptococcal infection (particularly
of the upper respiratory tract) and/or acute stressful life
events [21]. Generalized pustular psoriasis, as well as the
localized form and its variants (circinate or Bloch-Lapi` ere’s
pattern, acrodermatitis continua of Hallopeau) are charac-
terized by nonfollicular sterile pustules, which represent the
macroscopic aspect of the massive neutrophil inﬁltration of
epidermis [21, 22]. The erythrodermic form is dominated
by generalized erythema, loss of peculiar clinical features
of psoriasis, and skin failure, that is, inability to maintain
homeostatic functions [23]. Psoriatic erythroderma is not
substantially diﬀerent from erythroderma by other causes.
4. Psoriasis andMetabolicComorbidities
It has recently been found that psoriatic patients have a
higher prevalence of some metabolic disorders [24], par-
ticularly obesity, diabetes, or abnormal glucose intolerance,
dyslipidemia, and systemic hypertension, which together are
known as the metabolic syndrome [25] .P s o r i a s i si sn o w
also considered to be a marker of increased cardiovascular
risk, especially in young patients [26]. Psoriatic disease is
associated with unhealthy behaviors, particularly smoking
and obesity; in addition, it may inﬂuence metabolic and
cardiovascularriskindependentlyoflifestylefactors,through
common genetic risks, resulting in a chronic systemic
inﬂammatory pathway [27]. A recent study, evaluating
the association with comorbidities in psoriasis patients
in Italy, showed that, from a total sample of 511, 532
individuals, overall patients had more selected comorbidities
compared to healthy controls, in particular chronic ischemic
heart disease, obesity, diabetes mellitus, bronchitis, cardiac
valveabnormalities,dermatomycosis,benignmammarydys-
plasias, disorders of penis, disorders of external ear, inﬂam-
mation of eyelids, and contact dermatitis. In agreement
with previous studies, they found a signiﬁcant association of
psoriasis with cardiovascular risk factors (diabetes mellitus
and obesity) without, however, conﬁrming an association
with others (dyslipidemia and blood hypertension). In con-
trast, we found no signiﬁcant diﬀerence in general medical
history (e.g., cardiac diseases, diabetes) between psoriatic
and control groups, except for high blood pressure that was
more prevalent in psoriatic patients [28–31].
A causal link between psoriasis and cardiovascular
disease is hypothesized also for the involvement of the sameClinical and Developmental Immunology 3
mediators and markers of inﬂammation, mainly TNF-α,
IL-6, ﬁbrinogen, and C-reactive protein [6]. Apart from
these cytokines, insulin-like growth factor (IGF)-I, the
main anabolic mediator of somatotroph axis also acting as
an autocrine/paracrine signal essential for proliferation of
epidermal keratinocytes, has been found to be overproduced
in psoriatic epidermis. Despite the increase in IGF-I in
psoriatic plaques, psoriatic patients exhibited low circulating
levels of IGF-I, with a negative correlation to Psoriasis
Area and Severity Index (PASI). However, it is well known
that a number of inﬂammatory cytokines aﬀecting IGF-
I secretion and subtle changes in IGF-I levels have been
associated with unfavourable lipid proﬁles, with increased
cardiovascular mortality [32]. Thus, although abnormalities
in somatotroph axis activity have been hypothesized to
accountforthelowIGF-Ilevelsinthepsoriaticpatients,with
a possible primary or secondary eﬀect of these disturbances
on the psoriasis process modulation [33], the more likely
association of low IGF-I with the common inﬂammatory
pathways of both metabolic syndrome or psoriasis has not
been considered as far. On this basis, Savastano et al.
speculated that in psoriasis chronic inﬂammation might
be an important modulator of low IGF-I status and that,
similarly to other pathological conditions, low IGF-I status
could be added as a further possible mechanistic link
between psoriasis and associated metabolic comorbidi-
ties [34]. In conclusion, psoriatic systemic inﬂammation
may underneath insulin resistance, which in turn triggers
endothelial cell dysfunction, leading to atherosclerosis and
ﬁnally myocardial infarction or stroke [27].
5. Psoriasisand Malignancy
Although anti-TNF-α drugs mechanism of action has been
well investigated, long-term studies concerning malignancy
risk associated with these immunosuppressive agents have
been most extensively performed in rheumatoid arthritis
more than in psoriasis population; there are in fact just some
casereportsregardingthismatterinpsoriasis,suggestingthat
these therapies can permit malignant processes [35]. There-
fore,riskofmalignancywithanti-TNF-αinpsoriasisremains
unclear. However, the majority of reports indicate that TNF-
α inhibitors may cause a slightly increased risk of cancer,
includingnonmelanomaskincancerandhematologicmalig-
nancies [36, 37]. So far, it is worthy that oncologic personal
and familiar history, skin examination, and baseline blood
testsattemptingtoidentifyanyhematologicabnormalitiesbe
required before starting biologics therapy [35].
6.PsoriaticInfectiousComorbidities
(Other than TB)
TNF-αplaysanimportantroleinhostdefenseandanti-TNF-
α agents may theoretically increase the risk of infections.
Most recent studies suggest that anti-TNF-α agents are
associated with a slight increased risk of serious infections,
especiallyintheearlyphaseoftreatmentandanabsoluterate
of infections relatively low [38]. Grijalva analyzed whether
initiation of TNF-α antagonists compared with nonbiologic
drugs was associated with an increased risk of serious
infections in a cohort of patients aﬀected by rheumatoid
arthritis, inﬂammatory bowel disease, psoriasis, psoriatic
arthritis, or ankylosing spondylitis; rates were 5.41 for TNF-
α antagonists and 5.37 for traditional systemic drugs per 100
person-year, showing no signiﬁcant diﬀerence between the 2
groups [39]. Another recent systematic review showed that
there may be a small increased risk of overall infection with
short-term use of TNF-α antagonists in psoriasis, whereas
97.6% were nonserious infections and the large majority of
these were ones of the upper respiratory tract [40].
7. Psoriasis andTB
Recently, inﬂiximab, etanercept, adalimumab, and goli-
mumab have become the drugs of choice in the treatment
of these disorders. Of course, such kinds of drugs could
conceptually interfere with a cytokine, TNF-α,w h i c hi sc r u -
cial in the development and maintenance of the granuloma.
Moreover, the early diagnosis and treatment of individuals
harboring the Mtb is key to ensuring the eﬀectiveness of
health programs aimed at the elimination of TB. On the
otherhand,psoriasis“per se”couldrepresentanindependent
risk factor for TB since, interestingly, an unexpected high
prevalence was found in patients aﬀected by such a disease
(18.0%), even adjusting for age, work, and other parameters
[41]. A similar result is reported by Bassukas et al. during
a two-year period, LTBI diagnosis rate was compared in
consecutive patients with psoriasis or inﬂammatory bowel
diseaselikeCrohn’sdiseaseorulcerativecolitis:thesepatients
had signiﬁcantly smaller tuberculin skin testing compared
to psoriasis patients (P = 0.007). Applying LTBI diagnosis
guidelines, latent infection resulted in more psoriasis (50%)
than inﬂammatory bowel disease patients (24.2%), prior
to onset of any anti-TNF-α treatment (P = 0.04) [42]. A
recent survey concerning the evaluation of the infectious
complications during biological therapy of psoriasis showed
a rate of infections of 12.24%, with only one case of
pulmonaryTB,outof988patients[43].Theauthorsstressed
that such a result depend on a strict screening of LTBI,
prior to starting the biological treatment. A French report
showed that, in a mixed population of patients treated with
TNF-α blockers, including psoriasis, 45 cases were collected
of non-TB opportunistic infections (OIs). One-third (33%)
of OIs were bacterial (4 listeriosis, 4 nocardiosis, 4 atypical
mycobacteriosis, 3 nontyphoid salmonellosis), 40% were
viral (8 severe herpes zoster, 3 varicella, 3 extensive herpes
simplex, 4 disseminated cytomegalovirus infections), 22%
were fungal (5 pneumocystosis, 3 invasive aspergillosis, 2
cryptococcosis), and 4% were parasitic (2 leishmaniasis).
Ten patients (23%) required admission to the intensive care
unit, and four patients (9%) died. Risk factors for OIs were
treatment with inﬂiximab (OR = 17.6 (95% CI 4.3–72.9);
P<0.0001) or adalimumab (OR = 10.0 (2.3 to 44.4); P =
0.002) versus etanercept, and oral steroid use >10mg/day
or intravenous boluses during the previous year (OR = 6.3
(2.0 to 20.0); P = 0.002) [44]. Another study identiﬁed4 Clinical and Developmental Immunology
69 cases of tubercular active disease prospectively through
the French RATIO registry: the sex and age-adjusted TB
incidence rate was 1.17 per 1,000 patient-years, 12.2 times
that of the general population [45]. A similar conclusion
was reached by a Portuguese biologics registry study that
found the TB risk with anti-TNF-α antibodies to be 12-
fold greater than with etanercept [46]. S´ anchez-Moya et al.
report that, among one hundred and forty-four patients
with moderate-to-severe psoriasis treated with anti-TNF-α
agents, a total of 42 (29%) patients were diagnosed with
LTBI based on a positive tuberculin skin test (TST) or re-
TST, and/or signs of past TB in the chest X-ray. All of them
received chemoprophylaxis with isoniazid (H). Only one
patient developed an active lymphnode TB [47]. Besides, the
risk of active TB due to inﬂiximab appeared to be twice that
of etanercept [48]. Most of the active TB cases in patients
treated with TNF antagonists are due to reactivation of latent
infection with Mtb. TB in patients who have been treated
withTNFantagonisttherapiesusuallyprogressesrapidlyand
is frequently disseminated, with several extra-pulmonary
localizations. Thus, the most eﬀective way to avoid TB reac-
tivation is (and remains) treatment of the latent infection.
8. Management of TB Infection in
PsoriasisPatients
8.1. Conventional TST and Interferon Gamma Release Assays:
Overview on Test Characteristics. Screening for LTBI before
the initiation of any immune-suppressive therapy regimens,
including TNF-α blocking agents, is part of current man-
agement strategies of common inﬂammatory disorders such
as psoriasis, such an approach having been associated with
an estimated reduction of more than 80% of the risk of TB
reactivation [49, 50]. Guidelines for TB prevention suggest
taking a careful medical history and excluding active TB
before starting any kind of treatment. All patients should
be questioned regarding their demographic details (i.e., age
and country of birth), history of previous Bacillus Calmette-
Gu` erin (BCG) vaccination, TB risk factors (i.e., recent close
exposure to active TB cases, immigration from or recent stay
in high TB prevalence areas, and chest X-ray evidence of TB
sequelae), and current treatments (i.e., drugs) [51].
Diagnostic algorithms based on the use of the TST are
still in use worldwide for the detection of TB infection. As
known, TST is a measure of a delayed-type-hypersensitivity
response to the intradermal inoculation of PPD (puriﬁed
protein derivative), which is a mixture of more than 200
mycobacterial antigens. Despite TST is easy, safe, and inex-
pensive to administer, poor speciﬁcity limits its use because
of PPD cross-reactivity with environmental mycobacteria
and with the M. bovis BCG vaccine strains. In addition,
despite diﬀerent cut-oﬀ values are used to stratify PPD
reactors according to their likelihood to be infected and to
predict the risk of disease progression, sensitivity of TST
is signiﬁcantly reduced in the case of immune-compromise
where a TST-positivity is given by an induration area equal
or greater than 5mm [51, 52]. Finally, TST result may
not be stable over time as the reaction size may increase
due to a new infection (conversion) or to serial testing
in previously sensitized individuals (boosting). Reversion
to a negative TST result may also occur [53]. Overall,
these limitations explain why in the guidelines released by
the British Thoracic Society (BTS) for the management of
patients due to start anti-TNF therapies, the use of TST
was not recommended in patients with no TB risk factors,
while remaining controversial in high-risk cases due to the
expected high rate of false-negative results [54].
Recently, commercially available and FDA (Food and
Drug Administration) approved interferon gamma release
assays (IGRAs) have been introduced in clinical practice
as alternative tools for the identiﬁcation of Mtb infection.
Unlike TST, blood tests are based on the principle of
detecting IFN-γ  production by eﬀector memory T-cells
upon short term (16–20hrs) in vitro stimulation with TB-
speciﬁc antigens. Measurements of IFN-γ are performed
either by ELISpot-based assay (T-SPOT.TB, TS-TB, provided
by Immunotech, UK) or ELISA [QuantiFERON TB Gold
(QFT-G) and QFT-in-tube (QFT-IT), both provided by
Cellestis, Australia]. All tests rely on the use of two TB
speciﬁc antigens, that are early secretory antigen- (ESAT-) 6
and culture ﬁltrate protein- (CFP-) 10, mapped to a genomic
region called RD (region of diﬀerence)-1, which is absent
in the vaccine strains and in most non-TB mycobateria
(expect kansasii, szulgai, marinum, ﬂavescens,a n d gastrii)
[55]. To date, QFT-IT is the latest improvement of the
ELISA technology. It has widely replaced the previous in-
plate format (QFT-G) as blood samples are directly collected
into tubes pre-coated with antigens (also including a third
antigen, that is, the RD-11-related TB7.7) and ready for
incubation. Each test is provided of both a negative and a
positive control (phytohemagglutinin, PHA), thus allowing
a more comprehensive evaluation of the host immune
reactivity. Despite there is evidence that IGRAs performance
(i.e., QFT) may signiﬁcantly vary in comparison to TST
depending on the epidemiological and clinical setting [56,
57], overall, a pooled sensitivity of 87.5% and 81% has
been estimated in a recent meta-analysis, respectively, for
TS-TB and QFT-IT, as compared to TST (70%). Pooled
speciﬁcity has instead been evaluated at 86% for TS-TB and
99% for QFT-IT. The pooled estimated rate of indeterminate
results was low, 2.1% (95% CI, 0.02–0.023) for QFT-IT
and 3.8% (95% CI, 0.035–0.042) for TS-TB, increasing to
4.4%(95%CI,0.039–0.05)and6.1%(95%CI,0.052–0.071),
respectively, among immunecompromised hosts [58]. As for
TST, a main limitation of IGRAs is represented by the lack
of discrimination of LTBI from active TB. Reproducibility
in serial testing along with deﬁnitions of conversion and
reversion, diﬀerentiation of cut-oﬀ values for targeting
selected patient populations, positive predictive value, and
boosting remain as further areas of uncertainty that only in
parthaverecentlybeenaddressed,aselsewherediscussed[59,
60]. In conclusion, IGRAs testing requires the availability
of equipped laboratories with expertise in the ﬁeld and
adequate economic resources to ensure eﬃcient samples
turnover. Although intrinsic technical characteristics may
explain a certain degree of discrepancy when comparing
the performance of the two IGRA formats, current clinicalClinical and Developmental Immunology 5
evidence actually does not clearly favor one test over the
other in any setting.
8.2. TST and Advances on IGRAs Performance in Psoriasis
Patients. Nonetheless, some recent evidence still supports
that the use of TST is reliable as an eﬀective diagnostic
approach for the detection of TB infection, as suggested
by Sanchez-Moya et al. in a prospective evaluation of 144
patients aﬀected by moderate-to-severe psoriasis in Spain
[47], some concerns on TST application in this selected
patient population need to be addressed. TST may be
ineﬀective due to the dubious results that it generates in
patients with psoriasis as disease activity may substantially
aﬀect the test outcome [60]. First, it may be impossible
to ﬁnd lesion-free skin areas suitable for TST in patients
with severe skin disease. Secondly, the observation of an
increased TST reactivity of even healthy skin regions has
been associated with proinﬂammatory priming that leads to
an over-reaction to a wide spectrum of antigenic triggers
[61]. In this issue, Bassukas et al. [42] have recently shown
that patients with moderate-to-severe plaque psoriasis had
signiﬁcantly larger TST reactions compared to patients with
inﬂammatory bowel disease, as previously reported. To
overcome TST limitations, assessment of the value of IGRAs
as diagnostic tools in detecting LTBI in psoriasis patients
is currently under investigation, most of the studies being
focused on patient candidates for receiving anti-TNF agents
due to the high impact of such a therapy on TB risk [62,
63]. Chiang et al. [64]i nar e c e n tp r o s p e c t i v es t u d yﬁ r s t
used TS-TB as a unique diagnostic tool for TB infection
screening purposes in 63 patients aﬀected by severe psoriasis
in UK. The Authors found a prevalence of LTBI of 7.9%, the
IGRA test positivity being associated with a travel history
to TB endemic countries. A retrospective analysis carried
out in Switzerland over a 4-year period on 50 psoriasis
patients, the 90% with prior BCG vaccination, subjected
to both TST and TS-TB before the initiation of anti-TNF
treatment showed that a positive TS-TB result was strongly
associated with a presumptive diagnosis of LTBI, while this
was not the case for TST. Agreement between the two tests
was quite poor (κ = 0.33). LTBI treatment was avoided
in the 20% of patients tested positive by TST (≥5mm)
but negative by TS-TB (however, one case of disseminated
tuberculosis occurred despite LTBI treatment after 28 weeks
of therapy with adalimumab) [64]. More recently, a further
retrospective study conducted in Taiwan, an intermediate
TB burden country, has assessed the accuracy of QFT
in 147 psoriasis patients, including both cases with and
without treatment with TNF-alpha blocking agents (median
exposure of 24 weeks) [65]. Previous survey reports in this
setting have reported a TST-positive rate of 47% in the
general population aged 20–59 years old [66]. In the study
by Chiu et al. the percentages of LTBI in psoriasis patients
rangedfrom30%to36%,accordingtoTSTcut-oﬀused,that
was 10 or 5mm, respectively, the overall rate of QFT positive
tests being even lower (12%). Agreement with TST was poor
(63%, κ = 0.046). Despite this, unnecessary treatment of
LTBI was avoided in a signiﬁcant number of cases, active TB
developed in one out of four QFT-positive patients (25%)
thatwhilereceivingTNFblockingagentswerenottreatedfor
LTBI [65]. Finally, a cross-sectional study realized in Brazil
has shown that the frequency of TST-positive responses and
skin induration size were signiﬁcantly lower in 33 psoriasis
patients(18%;2.6±0.7mm)ascomparedto30casesaﬀected
by other common dermatological diseases (control group)
(53%; 9.3 ± 1.4mm) [67]. Conversely, frequencies of TS-
TB-positive results were not diﬀerent in psoriasis (47%) and
controlpatients(40%),whileapooragreementwithTSTwas
recorded in the formers (κ = 0.375). These ﬁndings conﬁrm
a previous observation of a decrease of central memory anti
TB immune responses in untreated psoriasis patients living
in endemic areas while they retained T-cell memory eﬀector
activity [68]. Overall, rates of indeterminate results were
quitelowrangingfrom1.6%(TS-TB)[63]to1.9%(QFT-IT)
[65]. As indeterminate results may reﬂect a high background
IFN-gamma production (negative control) or, alternatively,
the inability of the immune system to mount a T-cell
response (positive control), every attempt should be made
to clarify the reasons, also excluding technical errors, behind
this kind of results [69]. Head-to-head comparison studies
of TS-TB versus QFT are even more limited. In this issue,
we simultaneously tested a small cohort of patients aﬀected
by psoriasis or psoriatic arthritis with TST in comparison
with both TS-TB and QFT-IT. The main ﬁnding of the
study was a good agreement of blood tests with conventional
TST (κ = 0.86 and 0.84, resp.). This was not surprising
due to the high rate of negative results recorded as patients
were mainly represented by non-BCG vaccinated young
individuals without known TB risk factors, conﬁrming a
previous report [70]. However, in two TST-negative cases
(11%), IGRAs yielded a positive result that allowed the
identiﬁcation of a presumptive LTBI [71], thus supporting
using these assays in psoriasis patients [72]. Finally, only
a few studies to date report on the performance of TST
or IGRAs for monitoring patients already under treatment
with TNF-α blockers. Single-case reports and case series
have described psoriasis patients tested negative by TST but
positive by means of an IGRA [73, 74]. Clinical applicability
ofQFT-IThasbeenprospectivelyassessedin50patientswith
psoriasis along with TST while patients were on anti-TNF
therapy. Agreement among tests was moderate (κ = 0.408)
at baseline, good (κ = 0.734) at 6 months, and fair (κ =
0.328) at 12 months of treatment [75]. To date, TST+/QFT-
c a s e sw e r er e ga r d e da sn o ts u ﬀering from LTBI which instead
was 12 diagnosed based on QFT conversion alone. Overall,
current evidence including disease conditions other than
psoriasis suggests IGRAs results to be not interpretable in
this setting [76–78]. Longitudinal high-powered studies with
longer followup periods are necessary to optimize their use
and systematically assess whether IGRAs can be used in this
clinical scenario for monitoring a previous infection or for
regular screening purposes in high prevalence countries or
more speciﬁcally after an exposure event in low burden areas
in the case of occurrence of a new infection.
8.3. National Guidelines and Consensus Recommendations:
Points of Agreement and Criticisms. Actually, views on how
TST and IGRAs should be employed for LTBI screening6 Clinical and Developmental Immunology
are widely divergent and no speciﬁc recommendations in
the setting of patient candidates for receiving immune-
suppressive therapies are available [79]. Among the disease
conditions for which LTBI diagnosis is mandatory, psoriasis
occupies a unique position due to some speciﬁc disease-
associated issues. Overall, the present observations suggest
that TST-based screening algorithms may lead to over-
diagnosis of LTBI in patients aﬀected by overt plaque
psoriasis or, conversely, may be not applicable in the case of
extensive skin involvement. In addition, a likely impairment
of central memory T-cell responses leading to TST unre-
sponsiveness may further represent an issue of concern in
these patients, at least in TB endemic areas. This means that
innovative approaches are needed to overcome these limita-
tions through the readaptation of current guidelines while
suggesting a key role of IGRAs as ﬁrst-line diagnostics for
putative LTBI at least in patients with diﬀuse skin morbidity
and in the case of confounding factors, like previous BCG
vaccination. In 2005, the U.S. Centers for Disease Control
and Prevention (CDC) ﬁrst recommended the use of QFT-G
(the plate ELISA-based format available at that time) instead
of TST in all circumstances and clinical settings in which
TST was used [80]. However, this is not the same approach
recommendedinthelastupdatewherediﬀerentstrategiesare
suggested including testing with both an IGRA (with no test
format preference) and a TST in the case of high suspicion
of false-negative or false-positive results, indeterminate,
borderline, or invalid results [81]. In the European setting in
2006, the National Institute for Clinical Excellence (NICE)
guidelines proposed a cost-eﬀective two-step strategy that
is conﬁrmation of a positive TST result by any available
IGRA [82]. It was, however, suggested to consider IGRAs as
an alternative tool in the case of not reliability of TST or
of high suspicion of false-negative TST results in immune-
compromised patients. Later on, IGRA tests were oﬀered as a
suitable alternative to TST in all BCG-vaccinated individuals
within the context of this risk assessment by the Heath
Protection Agency (HPA) [83]. Despite the NICE guidelines
werenotfocusedonthemanagementofpatientstobetreated
with TNF blockers, Lalvani has recently suggested that it
may be prudent to perform both TST and any IGRA to
maximise diagnostic accuracy until stronger evidence on
blood tests use in this patient population has expanded
suﬃciently [55]. Despite the Canadian and Italian guidelines
which are in line with the NICE approach [84, 85], fur-
ther recommendations by national societies worldwide still
have divergent positions when targeting patient candidates
to immune-suppressive/anti-TNF therapies. To date, most
of them, except those from Switzerland and Germany,
recommend TST (mainly as a one-step strategy) as the
unique screening tool, with cut-oﬀ values ranging from 5 to
10mm in the diﬀerent geographic settings. Conversely, any
commercial IGRA is preferred instead of TST in Switzerland,
while Germany guidelines recommend the combined use
of TST (cut oﬀ ≥5mm) only in IGRA-negative cases with
clinically proven TB exposure [45, 50, 86–93]. The more
recent TBNET consensus statement [48], based on published
evidence and expert opinions, suggests using any IGRA,
or, as an alternative, the TST testing one-step strategy (cut
oﬀ ≥10mm) in patients with no prior BCG vaccination.
Repeated testing for TB infection may be considered in
patients with ongoing risks of exposure. In this case, the
use of TST is not strictly recommended due to the boosting
eﬀect. Overall, in all the scenarios proposed, no diﬀerences
among disease conditions to be targeted are considered and
no speciﬁc recommendations are proposed to tailor speciﬁc
disease phenotypes, such as severe skin psoriasis. In this
issue, the unique document speciﬁcally focused on psoriasis
patients provided by the National Psoriasis Foundation
suggests the use of TST as ﬁrst-line screening tool (cut-oﬀ
equal or greater than 5mm) and considering IGRA testing
in BCG-vaccinated patients. However, there is no mention of
speciﬁc disease subtypes [87].
8.4. Treatments Options for LTBI and Active TB. As recently
summarized in the TBNET consensus statement, recom-
mended treatment regimens for LTBI vary, their eﬃcacy
having not been evaluated in this setting. They mainly
include 6 or 9 months with H, 3 months of rifampicin (R)
plus H, and 4 months of R [48]. The time delay before
starting anti-TNF agents also diﬀers ranging from 3 weeks
to as long as possible after the initiation of TB prophylaxis,
dependingonthegeographicalcontext[45,50,86–93].Strict
adherence to treatment has to be strongly encouraged as
it signiﬁcantly reduces the patient risk to develop active
TB. Patients should be educated about signs and symptoms
of possible TB reactivation or of drug-induced side eﬀects.
Baseline and routine followup of liver enzymes should be
performed on a monthly basis. Repeated chest X-ray is not
recommended. Imaging of the thorax also including high-
resolution-computed tomography scan should instead be
performed without delay in the case of suspected active
TB. No action is required for patients having completed a
previous course of anti-TB treatment unless a reinfection
is plausible. Treatment regimens are recommended in the
case of active TB according to international standards as for
susceptible immune-competent patients [94]. No diﬀerences
in treatment duration have been suggested as actually there
is no evidence for the need of any prolongation. The
optimal timing for the initiation of TNF-blocking therapies
is unclear, in some instances being recommended after
the completion of at least 2 months of anti-TB treatment.
Expert opinion in agreement with the CDC conversely
suggests waiting until the end of a full course. Maintaining
vigilance for TB even after the completion of appropriate
treatment strategies (LTBI/active TB) remains of utmost
clinical relevance.
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